本帖最后由 老马 于 2013-3-13 13:43 编辑 ' |1 ?+ I, O; F, }
6 W. t6 C6 ~! e+ { H# N
健择(吉西他滨)+顺铂+阿瓦斯汀
1 w3 ~+ e4 x2 _) I+ s Gemzar +Cisplatin + Avastin
/ q+ }6 w9 c5 ?2 k: @http://annonc.oxfordjournals.org/content/21/9/1804.full
$ R! X5 G6 p. d- _; ?8 B' {Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. v5 w7 X7 Q2 w; v! X9 w( T$ yPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* |+ T/ {- h2 q8 G7 fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 0 `0 s9 ?; G. _
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 228)
& \7 u7 W; v$ o; u0 t: Z- E华为网盘附件:
/ Y, J# {, b; ]【华为网盘】ava.JPG
4 U4 C: F+ H. C& Q" b |